In the Press
March 12, 2020

As Coronavirus Spreads, A Biotech IPO Squeaks Through. Others May ‘Wait and See’ (BioPharma Dive)


Biotech companies seeking to go public in the U.S. face a stiff test during the surging outbreak of the new coronavirus, which is dragging down the stock market as the risks to the broader economy become real. Goodwin’s Michael Bison, a partner in the firm’s Life Sciences group and Capital Markets practice, discusses the potential damage and issues IPO hopefuls will face moving forward while remaining optimistic. Read the article here.